ANDA 205135, held by Sun Pharmaceutical Industries. Methylphenidate Hydrochloride.
As of Nov 21, 2026, ANDA 205135 (Methylphenidate Hydrochloride), held by Sun Pharmaceutical Industries, was first approved by FDA on Aug 19, 2020, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 19, 2020 | Original application | Approved | None posted |
| Methylphenidate Hydrochloride18MG · tablet, extended release;oral | Methylphenidate Hydrochloride | Discontinued |
| Methylphenidate Hydrochloride27MG · tablet, extended release;oral | Methylphenidate Hydrochloride | Discontinued |
| Methylphenidate Hydrochloride36MG · tablet, extended release;oral | Methylphenidate Hydrochloride | Discontinued |
| Methylphenidate Hydrochloride54MG · tablet, extended release;oral | Methylphenidate Hydrochloride | Discontinued |
| Nov 16, 2026 | Supplement 11Labeling · Standard review | Approved | None posted |
| Nov 16, 2026 | Supplement 10Labeling · Standard review | Approved | None posted |
| Nov 16, 2026 | Supplement 9Labeling · Standard review | Approved | None posted |
| Nov 16, 2026 | Supplement 6Labeling · Standard review | Approved | None posted |
| Sep 7, 2023 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 19, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters